Following strict hygiene protocols is crucial
By using our cutting-edge methodology, we aim to not only treat current pigmentation problems but also stop them from coming back in the future

Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans

I was too tired to exercise
Also nasal spray devices are typically 12.0 units per spray (125uL) The solution to get that into 4 sprays containing 20mg per spray (1 dose) = 80mg delivered would be a 16% concentration
Start (Weeks 12): 20 mcg once daily to assess tolerance, particularly any effect on blood glucose